Our Team
Leading Pacific Marine Biotech to discover and deliver to the world our cutting edge, medical discoveries is a global team of professionals and staff.
Board of Directors
David S. Harburger, Ph.D.
David Harburger is a patent attorney working closely with life sciences clients from the early stages of formation and beyond to align their intellectual property
Advisory Board
Kevin Sweeney, M.D., Medical Advisor
Dr. Kevin Sweeney is a distinguished neurosurgeon with a remarkable career dedicated to advancing neurosurgical care. He earned his undergraduate degree from Illinois Wesleyan University
Michael C. Magnifico, MD, Medical Advisor
Michael Magnifico, MD, holds three board certifications: internal medicine, medical oncology and hematology. During his decades of clinical practice, he directly cared for patients throughout
Santosh Kesari, M.D., Ph.D., Medical Advisor
Dr. Santosh Kesari is a distinguished neurologist and neuro-oncologist renowned for his contributions to brain cancer research and treatment. He serves as the Chair and
Medical Advisors
Australia Clinical Trials
PMB announces the provisional approval of our Phase 2 clinical trial aimed at investigating the efficacy of Immune-12 in treating Glioblastoma Multiforme (GBM) in Australia…
Registered with the Australian New Zealand Clinical Trials Registry (ANZCTR) under registration number ACTRN12624001484538p, this trial will involve 60 patients and marks a significant step in our global research efforts… Patient recruitment is now underway…
As we collaborate with esteemed Australian clinical researchers, we are dedicated to developing a robust protocol that leverages local expertise to enhance treatment outcomes for GBM….
USA Clinical Trials
We recently updated our milestone timeline for US based clinical trials which will be done in association with our ongoing FDA reviews and approvals.
Legal Advisor
World Federation of Neuro-Oncology Societies
PMB plans to attend the 7th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies, held in conjunction with the 30th Society for Neuro-Oncology Annual Meeting & Education Day in beautiful Honolulu, Hawaii! This year’s meeting is particularly special, as we celebrate SNO’s 30th anniversary—a milestone that underscores three decades of progress, collaboration, and innovation in neuro-oncology.
17th COGNO Annual Scientific Meeting (ASM)
Immune12 researcher at the Southern Cross University, Dr. Janet Schloss, is sharing an abstract at the upcoming17th COGNO Annual Scientific Meeting (ASM), New Horizons, Novel Therapies to be held Sunday 14 September – Tuesday 16 September 2025 at The Langham Gold Coast, Queensland.
2025 LSX World Congress
PMB will be joining the LSX USA Congress in Boston, September 16–17!
We look forward to collaboration on biotech advancements such as Immune12, our groundbreaking marine-sourced complex biologic targeting Glioblastoma (GBM), one of the most aggressive forms of brain cancer.
If you’re active in oncology, biologics, or exploring investment opportunities in next-gen therapeutics, we would love to connect. Let’s talk science, strategy, and the future of neuro-oncology.
Anti-inflammatory Activity of Sea Cucumber Supplements
A human food supplement (SeaCare (R)) composed of dried extracts from specific varieties of holothurians (sea cucumbers) and a sea plant has been found to have anti-inflammatory activity in both sexes of two strains of rats. It is slightly less active than aspirin (w/w) against the acute carrageenan-induced paw inflammation, but without the gastrotoxicity of aspirin. It is also active against adjuvant-induced polyarthritis in rats on a daily dose schedule
A Phase II Trial of TBL 12 Sea Cucumber Extract In Patients With Untreated Asymptomatic Myeloma
Patients with smoldering multiple myeloma (MM) may remain asymptomatic (ASx) for variable amounts of time and are therefore typically monitored without treatment. Chemoprevention trials using thalidomide found prohibitive toxicity and longer follow up is needed for early systemic treatment with lenalidomide/ dexamethasone of high risk ASxMM. Based on encouraging preclinical data with bioactive food supplements in MM curcumin (Blood 2003), resveratrol (Blood 2006), and a component of green tea extract (Blood 2006) many patients are already using these agents without definitive proof of efficacy or safety. Preclinically,
Financial Advisor
Andrew S. Verderame, MBA, RAC
Andrew S. Verderame, MBA, RAC leads the FDA Regulatory LLC Consulting group and is our Strategic Regulatory Affairs Advisor as we plan for and conduct
Andrew Satterlee, PhD
Andrew Satterlee, PhD, is an Assistant Professor and Founding Director of the Screening Live Cancer Explants Program and Core Facility based within Eshelman Innovation, an
Scientific Advisors
Today Tonight Australia
Hear the stories of several early adopters as produced and aired by the popular Australian television show Today Tonight Australia.